Market Overview
Size, mix, and treatment need
- Brevintel analysis values the antiparasitic drugs market at USD 20.7 billion in 2025 ($20.7B), expanding from USD 21.7 billion in 2026 to USD 36.2 billion by 2035 ($36.2B) at a 5.8% CAGR.
- Historical growth was 4.8%, with market value increasing from USD 17.9 billion in 2022 to USD 19.7 billion in 2024.
- GlaxoSmithKline led with over 12% market share in 2025, while GlaxoSmithKline, Novartis, Dr. Reddy's Pharmaceuticals, Sanofi, and Cipla collectively held 45%.
- Antiparasitic drugs treat infections caused by protozoa, helminths, and ectoparasites across mass drug administration, hospital care for severe disease, and commercial dispensing.
- WHO reported an estimated 282 million malaria cases and 610,000 malaria deaths in 2024, with the WHO African Region accounting for 95% of malaria deaths.
- Soil-transmitted helminth infections affect about 1.5 billion people globally, sustaining demand for albendazole, mebendazole, ivermectin, and praziquantel.
- In 2023, approximately 1.495 billion people required interventions against neglected tropical diseases, despite a substantial reduction from the 2010 baseline.
- Demand therefore combines low-cost, high-volume generic products with specialized formulations used in hospital and travel-medicine settings.
Purchasing systems and value mix
- Brevintel analysis finds expansion is supported less by uniform prescribing growth than by distinct purchasing systems: government-funded mass drug administration, hospital treatment, and commercial dispensing for endemic, travel-related, and imported infections.
- The projected rise from USD 21.7 billion in 2026 to USD 36.2 billion in 2035 reflects this diversified demand base rather than a single commercial channel.
- The U.S. President's Malaria Initiative has invested approximately USD 10 billion since 2006 and received USD 795 million in FY2024 appropriations for activities across partner countries in Africa and Southeast Asia.
- Clinical burden remains concentrated in lower-income endemic settings, while a meaningful share of market value is generated in countries with stronger diagnostic capacity and higher spending per treated case.
- Malaria, helminthic disease, leishmaniasis, trypanosomiasis, and ectoparasitic infections create differentiated demand for oral, injectable, and topical products rather than a single therapeutic format.
- WHO identified strongyloidiasis as a priority for expanded preventive chemotherapy, particularly in endemic settings with material prevalence among school-age children.
- Public-health treatment programs convert epidemiological burden into structured, recurring procurement that differs from conventional retail pharmaceutical purchasing.
- The commercial implication is that suppliers need both tender-scale manufacturing economics and the regulatory capability to serve higher-value specialty and hospital channels.
Market Dynamics
Demand drivers
- Parasitic disease prevalence remains the principal volume driver: WHO recorded 282 million malaria cases in 2024, while soil-transmitted helminths continue to affect approximately 1.5 billion people.
- WHO reported HRP2/HRP3-deleted Plasmodium falciparum parasites in 42 endemic countries during 2024, which can reduce the reliability of some rapid diagnostic tests and delay targeted treatment.
- Government and donor programs create predictable purchase cycles, including approximately USD 10 billion invested by the U.S. President's Malaria Initiative since 2006 and USD 795 million in FY2024 appropriations.
- WHO reported that more than 27.7 billion tablets and vials for neglected tropical diseases were delivered between 2011 and 2023, including approximately 2.1 billion in 2023.
- WHO's 2024 strongyloidiasis guideline further recommends annual ivermectin mass drug administration in qualifying endemic settings, expanding the institutional pathway for anthelmintic procurement.
- CDC surveillance identified increased imported malaria cases in several U.S. southern border jurisdictions in association with migration through malaria-endemic countries.
- European surveillance documented more than 34,000 imported malaria cases across reporting countries during 2015–2019, supporting hospital and travel-medicine demand outside endemic regions.
- WHO reported that more than 860 million people received treatment for neglected tropical diseases in 2023 through mass drug administration or individual case management.
Constraints and structural tension
- Artemisinin partial resistance has been identified in Plasmodium falciparum isolates from Ethiopia, alongside parasites with HRP2/HRP3 deletions that can evade standard rapid diagnostic tests.
- Evidence from a One Health review indicates resistance across major anthelmintic classes in animal populations, including benzimidazoles, macrocyclic lactones, and levamisole.
- The pipeline for several parasitic diseases remains limited relative to resistance risk, with attrition, supply constraints, intellectual-property barriers, and formulation challenges impeding translation.
- Pipeline scarcity is particularly material for kinetoplastid diseases, where commercial returns may not support conventional research investment.
- Partnerships involving organizations such as Medicines for Malaria Venture and the Drugs for Neglected Diseases initiative have advanced products, but they do not eliminate the funding gap across all indications.
- Brevintel analysis indicates that the market's primary structural tension is between expanding treatment need and the declining reliability of some established therapies.
- Public-health programs can sustain large medicine volumes, but they also expose suppliers to tender pricing, country-level registration requirements, and periodic shifts in treatment protocols.
- The forecast growth profile therefore depends on whether public procurement, philanthropy, and commercial specialty markets can collectively sustain essential generic supply and development of differentiated therapies.
Segmentation Analysis
Drug type
- Anthelmintics held the largest market share at 50.21% in 2025 and are projected to grow at a 6.7% CAGR, reaching USD 18 billion by 2035.
- Their scale reflects broad use against soil-transmitted helminths, schistosomiasis, lymphatic filariasis, strongyloidiasis, and other worm infections.
- High-volume medicines such as albendazole, mebendazole, ivermectin, and praziquantel are central to preventive chemotherapy and routine treatment, with repeat cycles and tender volumes shaping competition.
- Antiprotozoal drugs accounted for 21.75% of market revenue in 2025 and are projected to record the fastest drug-type CAGR at 7.23%.
- The antiprotozoal segment includes antimalarials and products used for leishmaniasis, giardiasis, trypanosomiasis, and amoebic disease, with 282 million malaria cases in 2024 as its largest epidemiological foundation.
- Novartis reported positive Phase III results for ganaplacide/lumefantrine solid dispersion formulation in November 2025, representing a potential alternative treatment approach for uncomplicated malaria.
- Ectoparasiticides represented 15.44% of market revenue in 2025 and are forecast to grow at a 6.81% CAGR, covering scabies, lice, and other ectoparasitic infestations through topical and oral formulations.
- Other drug types accounted for 12.60% of market revenue in 2025 and are projected to grow at a 6.25% CAGR, including specialized products that do not fit the core anthelmintic, antiprotozoal, or ectoparasiticide classifications.
Route of administration
- Oral products held the largest route-of-administration share at 54.10% in 2025, equivalent to USD 11.2 billion, and are projected to grow at a 7.41% CAGR.
- Tablets, dispersible products, capsules, and suspensions are compatible with mass drug administration, outpatient prescribing, and retail dispensing in schools, rural communities, and primary-care settings.
- WHO's neglected tropical disease roadmap identifies the need for age-appropriate formulations, including pediatric products for schistosomiasis treatment.
- Injectables represented 31.55% of market revenue in 2025 and are projected to grow at a 6.56% CAGR.
- The injectable segment serves severe malaria, visceral leishmaniasis, advanced trypanosomiasis, and other cases requiring supervised administration through hospital infrastructure.
- Topical products accounted for 14.35% of market revenue in 2025 and are projected to expand at the fastest route-level CAGR of 7.66%.
- Topical permethrin and ivermectin products are commonly used for scabies and lice, where localized delivery can reduce systemic exposure and support outpatient treatment.
- Formulation research is exploring nanoparticle-enabled topical delivery to improve drug release and pharmacokinetic performance relative to conventional preparations.
Distribution channel
- Hospital pharmacies held the largest distribution-channel share at 43.11% in 2025 and are forecast to grow at a 6.22% CAGR.
- They dispense treatments for severe malaria, visceral leishmaniasis, neurocysticercosis, and complicated strongyloidiasis, and they support high-volume tenders for public-sector programs.
- Retail pharmacies accounted for 31.67% of market revenue in 2025 and are projected to grow at a 7.78% CAGR.
- Retail pharmacies provide accessible distribution for oral anthelmintics, antiprotozoals, and ectoparasiticides, particularly where patients may seek treatment before reaching hospital services.
- Online pharmacies represented 25.22% of market revenue in 2025 and are projected to grow at the fastest channel CAGR of 8.02%.
- Digital dispensing is most relevant for repeat oral treatments, travel-medicine consultations, and patient access in markets with established e-prescribing and licensed delivery systems.
- Brevintel analysis suggests that the market's fastest-growing revenue pools are not necessarily its highest-volume treatment pools.
- Anthelmintics remain the largest category because mass treatment programs require large volumes of low-cost oral medicines, whereas antiprotozoals grow faster because resistance, combination therapy, and more complex clinical indications raise the value captured per course of treatment.
Regional Outlook
North America and Europe
- North America held the largest regional share at 36.77% in 2025 and is projected to grow at a 6.34% CAGR.
- The United States remains the principal market, increasing from USD 6.1 billion in 2022 to USD 6.8 billion in 2025.
- The region combines advanced diagnostics, high healthcare spending, established hospital infrastructure, and demand related to travel-associated and imported parasitic disease.
- CDC surveillance documented increased imported malaria cases in several southern U.S. border jurisdictions during 2023.
- Europe accounted for USD 5.9 billion in 2025, representing 28.56% of the market, and is forecast to grow at a 7.33% CAGR.
- European demand is supported by specialist infectious-disease services, cross-border travel, migrant health needs, and structured surveillance for zoonotic and foodborne disease.
- Imported malaria remains relevant, with more than 34,000 cases recorded across European reporting countries between 2015 and 2019.
- Brevintel analysis expects North America to retain market leadership through 2035 because its 36.77% 2025 share reflects value generated per treated case rather than global disease burden.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific accounted for 23.22% of global revenue in 2025 and is projected to grow at the highest regional CAGR of 8.23%.
- The region combines large endemic populations, variable sanitation conditions, improving healthcare access, and substantial pharmaceutical manufacturing capacity.
- India is particularly important because national programs address malaria, lymphatic filariasis, visceral leishmaniasis, and helminthic disease, including continued albendazole distribution for lymphatic-filariasis elimination.
- China's WHO malaria-free certification illustrates how sustained surveillance and treatment can change the regional demand profile from malaria control toward other parasitic conditions and imported infections.
- Latin America held a 6.10% share of the market in 2025 and is forecast to grow at a 6.0% CAGR.
- Brazil is the largest Latin American contributor because of its population, broad tropical geography, and public healthcare procurement capacity, with malaria, leishmaniasis, Chagas disease, and helminthic infections maintaining a diversified demand base.
- Middle East and Africa accounted for 5.35% of global revenue in 2025 and are projected to grow at a 5.67% CAGR.
- WHO reported that 95% of malaria deaths in 2024 occurred in the African Region, yet market value is limited by constrained purchasing power and reliance on donor-supported procurement, while Gulf markets contribute more conventional commercial demand.
Competitive Landscape
Structure and recent developments
- The market is moderately consolidated, with the five leading companies accounting for approximately 45% of global revenue in 2025.
- GlaxoSmithKline led with over 12% market share in 2025, and competition is determined by portfolio coverage, manufacturing scale, registration capabilities, quality compliance, tender participation, and channel access.
- Cipla received U.S. FDA final approval for albendazole tablets through the abbreviated new drug application pathway, strengthening access to the U.S. generic anthelmintic market.
- Dr. Reddy's Laboratories received U.S. FDA approval for hydroxychloroquine sulfate tablets for malaria treatment in July 2021.
- GlaxoSmithKline has a substantial anthelmintic position through Zental and, in June 2022, reaffirmed commitments to donate albendazole for lymphatic-filariasis control and other neglected tropical disease programs.
- Swissmedic approved Novartis Coartem Baby in July 2025 for newborns and young infants, with additional approvals anticipated in African countries through the Marketing Authorization for Global Health Products pathway.
- Novartis also reported positive Phase III KALUMA results for ganaplacide/lumefantrine in November 2025.
- In December 2023, the EMA Committee for Medicinal Products for Human Use issued a positive scientific opinion for Sanofi Fexinidazole Winthrop for acute T. b. rhodesiense sleeping sickness.
Integrated producers
- GlaxoSmithKline
- Novartis
- Sanofi
- Teva Pharmaceuticals
Specialty suppliers
- Cipla
- Dr. Reddy's Laboratories
- AdvaCare Pharma
- Ajanta Pharma
- Alkem Laboratories
- Cadila Pharmaceuticals
- Intas Pharmaceuticals
- Ipca Laboratories
- Mankind Pharma
- Weefsel Pharma